Selenium added to cancer drugs in new kidney cancer trial

This study is testing whether adding a selenium supplement (Seleno-L Methionine) to two standard cancer drugs (axitinib and pembrolizumab) is safe and more effective for treating advanced kidney cancer. It will involve about 55 adults with a specific type of kidney cancer that has spread or cannot be surgically removed. The research first aims to find the safest dose of selenium, then see if the three-drug combination helps shrink tumors better than the standard two-drug treatment alone.